Pharmaceutical companies everywhere have been shrinking their research budgets, but Elan Corporation Plc has gone one step further. It is spinning out its research department to shareholders. This will put the Ireland-incorporated company immediately into profit. Moreover, profits will be sheltered from tax in future years by a large tax loss carried forward from previous years.
